Anthos Therapeutics, a clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). This represents the second Fast Track designation Anthos has received in less than two months, with the FDA also assigning this designation to abelacimab for cancer-associated thrombosis (CAT) in July 2022. Earlier this year, abelacimab also became the first-ever Factor XI inhibitor to begin enrolling patients in phase 3 trials.
